Core Insights - Elicio Therapeutics is advancing its investigational cancer vaccine ELI-002 7P, targeting mKRAS-driven solid tumors, with preliminary data from the AMPLIFY-7P Phase 1a study showing promising early results in disease-free survival (DFS) [1][5][6] - The study involved 14 patients, with a median follow-up of 29.1 weeks, indicating a correlation between strong T cell responses and reduced tumor biomarker levels, suggesting potential efficacy of ELI-002 [1][6] - ELI-002 is designed to target seven common KRAS mutations, potentially expanding the patient population for treatment [7][8] Study Details - The AMPLIFY-7P study is evaluating the 7-peptide formulation of ELI-002 in patients with minimal residual disease after standard treatment [1] - As of the May 24, 2024 data cutoff, the median DFS has not yet been reached for patients receiving the 4.9mg AMP-peptide dose, while those receiving the 1.4mg dose had a median DFS of 12.6 weeks [6] - Patients with a reduction in tumor biomarker levels showed no progression events, contrasting with a median DFS of 11.0 weeks for those without such a response [6] Company Overview - Elicio Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer treatment, utilizing its AMP technology to enhance immune responses [8] - The company's pipeline includes ELI-002, targeting mKRAS-driven cancers, as well as other candidates targeting BRAF-driven cancers and p53 hotspot mutations [8]
Elicio Therapeutics Announces Preliminary Disease-Free Survival analysis from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P